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Background. Sentinel node biopsy (SNB) represents the standard of care in breast cancer axillary evaluation. Our study aims to
characterize the patterns of malignant cell distribution within the sentinel nodes (SN). Methods. In a retrospective IRB-approved
study, we examined the anatomic location of the nodal area with the highest radioactive signal or most intense blue staining (hot
spot) and its distance from the metastatic foci. Results. 58 patients underwent SNB between January 2006 and February 2007. 12
patients with 19 positive SN were suitable for analysis. 4 (21%) metastases were located in the nodal hilum and 15 (79%) in the
cortex. 6 (31%) metastases were found adjacent to the hotspot, and 9 (47%) within 4mm of the hotspot. Conclusions. In our pilot
series, SN metastases were within 4mm of the hotspot in 78% of the cases. Pathologic analysis focused in that area may contribute
to the more accurate identiﬁcation of nodal metastases.
1.Introduction
The technique of sentinel node biopsy with lymphatic
mapping has revolutionized breast cancer surgery, reducing
the resultant risks of undesired consequences from more
extensive axillary surgery and leading to the detection of
increasingly smaller metastatic foci in the axilla. Surgeons
strive to achieve a singular surgical intervention to the axilla
by identifying those patients with positive sentinel nodes
who would beneﬁt from further nodal dissection. Several
intraoperative techniques for lymph node evaluation are
available including frozen section, touch imprint cytology,
and RT-PCR breast lymph node (BLN) assay. These tech-
niques have variable sensitivities and high speciﬁcity and
involve diﬀerent degrees of nodal tissue manipulation.
We hypothesize that a better understanding of the
distribution of the metastatic foci within the sentinel lymph
node may aid in their more accurate detection and better
utilization of intraoperative evaluation techniques.
2. Methods
The study was reviewed and approved by the IRB. Patients
with invasive breast cancer who underwent sentinel node
biopsy at our institution by a single surgeon between
January 2006 and February 2007 were eligible for the
study. The sentinel nodes were identiﬁed after the injection
of intradermal radioactive Tc99-labeled sulfur colloid and
subareolar methylene blue.
The radioactive nodes werescanned with agammaprobe
intraoperatively, and the area of highest radioactivity (hot
spot) was identiﬁed and marked with a clip. Isotopically
nonactive nodes were clipped at the site of maximum blue
stain intensity. During subsequent routine pathologic exam-
ination, the hotspot was inked by the pathology technician,
and the clip was removed. Data regarding the anatomic
location of the hot spot and its distance from the metastatic
foci in the positive sentinel nodes was collected. The charts
were retrospectively reviewed.
3. Results
Fifty-eight patients with invasive breast cancer undergoing
sentinel node biopsy for a clinically negative axilla at our
institution by a single surgeon between January 2006 and
February 2007 were identiﬁed, yielding a total of 127
removed sentinel nodes. Of these patients, 42 had a negative
sentinel node biopsy and were excluded. In three cases,2 International Journal of Breast Cancer
the clip marking the hot spot was not present at the
time of pathologic examination. One other patient had a
positive sentinel node that was completely replaced with
metastatic disease. These four patients were also excluded
from the study. Patients who had been identiﬁed by axillary
ultrasound-guided ﬁne-needle aspiration as node positive
were not included in the study group.
A total of 12 patients with 19 positive sentinel nodes
fulﬁlledinclusioncriteriaandwereanalyzed.Thepatientand
tumor characteristics are listed in Table 1.
The majority of the tumors were inﬁltrating ductal
carcinomas (66.6%), and all were ER and/or PR positive. Of
the 19 nodes evaluated, 3 (16%) were positive for isolated
tumor cells (ITC), 8 (42%) contained micrometastases, and
8 (42%) macrometastases. The mean size of the examined
positive lymph nodes was 10.9mm, ranging from 5mm to
21mm and the mean size of the metastases 6.3mm, ranging
from ITC to 11mm. The hotspot was located in the nodal
cortex in 16 (85%) of the examined positive nodes. The 95
negative nodes in our cohort were also examined, and the
hot spot was found in the cortex in 77 (81%) of nodes.
In the nodes with tumor cells, the metastatic focus was
located in the nodal cortex and adjacent medulla in 15
(79%) of the nodes (Figure 1) and in the nodal hilum in
the remaining 4 (21%) nodes (Figure 2). Of the 4 nodes
that had the metastatic focus in the hilum, one contained a
micrometastasis and the other three macrometastases. The
metastatic focus was located immediately adjacent to the
marked hot spot in 6 (31%) nodes and within 4mm of the
hot spot in 9 (47%). Therefore, in 81% of the cases, the
hotspot was located in the cortex, and in 78% of the cases
the metastases were within 4mm of the hotspot (Table 2).
4. Discussion
Sentinel node biopsy represents the standard of care for
axillaryevaluationinpatientswithbreastcancer.TheNSABP
B-32 phase III clinical trial comparing sentinel lymph node
biopsy to conventional axillary lymph node dissection in
clinicallynodenegativepatientsshowedequivalentoutcomes
in overall survival, disease-free survival, and regional control
with decreased morbidity in the sentinel node group [1, 2].
More recent data on patient-reported outcomes for sentinel
lymph node biopsy versus axillary lymph node dissection
showed that in the ﬁrst six to twelve months axillary
node dissection patients reported ipsilateral arm and breast
morbidity, impaired quality of life, restricted work, and
social activity more than the sentinel lymph node resection
group. By twelve to thirty-six months, less than 15% in each
group had any residual symptoms [3].
In patients found to have positive nodes on sentinel
node biopsy, the standard of care has been to perform a
completion axillary node dissection either at the time of
the initial surgery or at a later date. In evaluating outcomes
based on timing of the dissection, the ACoSOG Z-0010
and Z-0011 trials demonstrated that patients who undergo
immediate as opposed to delayed completion axillary node
dissection experience more short-term morbidity, but long-
term outcomes were the same in both groups [4]. However,
Table 1: Patient and tumor characteristics.
Study population
N: 12 (100%)
Age (years)
Mean 55
Range 44–79
Histologic type
IDC 8 (66.6)
ILC 2 (16.6)
Mixed IDC/ILC 2 (16.6)
Tumor stage
IIA 6 (50)
IIB 1 (8.3)
IIIA 5(41.6)
Tumor grade
I 2 (16.6)
II 8 (66.6)
III 1(8.3)∗
LVI
Present 7 (58.3)
Absent 5(41.6)
ER/PR status
ER and/or PR positive 12 (100)
ER/PR negative 0
Her2neu 1 (8.3)
Positive 11 (91.6)∗∗
Negative
∗Onepatienthadreceivedneoadjuvantchemotherapysotumorgradeisnot
available.
∗∗IHC was performed ﬁrst and if intermediate FISH was done.
IDC: inﬁltrating ductal carcinoma, ILC: inﬁltrating lobular carcinoma,
LVI: lymphovascular invasion, ER: estrogen receptor, and PR: progesterone
receptor.
clearly, the duration to recovery is signiﬁcantly greater when
reoperation is required.
In an eﬀort to reduce reoperation, several techniques
have been developed for intraoperative lymph node evalu-
ation including frozen section, touch imprint cytology, and
RT-PCR breast lymph node (BLN) assay. All techniques
aim to accurately detect metastatic disease intraoperatively
and allow the appropriate patient to proceed directly to
axillary dissection. The sensitivity of touch imprint cytology
hovers around 70% with a speciﬁcity of over 95% [5,
6]. High false negative rates have been noted in cases
of micrometastases and invasive lobular carcinoma. Intra-
operative frozen section, though reported to have similar
sensitivity and speciﬁcity to touch imprint cytology, involves
the undesirable loss of tissue for permanent section analysis,
as well as longer turn around time and greater expense [7].
S e v e r a ls t u d i e sh a v eb e e np e r f o r m e dt oe v a l u a t eg e n e -
search real-time RT-PCR breast lymph node (BLN) assay in
detecting intraoperative metastases in sentinel lymph nodes
greater than 0.2mm [8]. This method identiﬁes mRNA
from cytokeratin 19 (CK19) and mammaglobin(MG) genes
expressed in epithelial cells but not present in lymphoidInternational Journal of Breast Cancer 3
Figure 1: Micrometastases located in cortex close to hotspot.
Figure 2: Micrometastases located in hilum close to hotspot.
Table 2: Results.
Total Sentinel Nodes Cortex Hotspot Hilum Hotspot
Positive (19) 15 (79%) 4 (21%)
Negative (95) 77 (81%) 18 (19%)
tissue. The nodal tissue is homogenized and using RT-PCR,
and the mRNA is ampliﬁed and metastases identiﬁed. When
compared to standard hematoxylin and eosin (H&E) stain-
ing,BLNachievesasensitivityof95.7%formacrometastases,
60.0% for micrometastases, and 55.6% for isolated tumor
cells [9]. Though the accuracy of BLN assay is comparable
to permanent section, it has not been rapidly adopted
acrossthe countrywithcriticisms centeredaroundthe 30–40
minute turn around time, the specimen loss associated with
tissue processing, the setup costs and the need for a skilled
technician to perform the study.
At this point, the indications for the use of all of
these techniques are under reevaluation in view of recently
published data from ACoSOG Z-0011 regarding the impact
of completion axillary node dissection in patients with
1–3 positive sentinel nodes [10, 11]. This trial evaluated
the impact of axillary dissection on both locoregional
recurrence and overall survival in patients undergoing breast
conservation therapy who were found to have one to
three positive sentinel nodes, by randomizing patients to
axillary dissection or no further surgery. Both groups were
treated with adjuvant systemic therapy and whole breast
radiotherapy, and, after six years of follow-up, there was
no diﬀerence in locoregional recurrence or survival. While
these results suggest that simply identifying patients as node
positive will provide adequate information for planning
systemic therapy, the results remain inapplicable to patients
who have undergone neoadjuvant chemotherapy, those with
greater nodal burden than represented in the study, and
those patients who will not be receiving radiation, due
to planned omission, mastectomy, or contraindications to
radiotherapy. In these scenarios, characterizing the sentinel
node intraoperatively still merits attention.
Yet a separate question remains as to whether the type
or distribution of metastases is important. Macrometastases
by deﬁnition are those tumor foci greater than 2mm. The
seventh edition of American Joint Committee on Cancer
(AJCC) staging for breast cancer deﬁnes micrometastases as
tumor deposits greater than 0.2mm but less than 2mm and
are designated pN1(mic) [12]. Isolated tumor cells (ITC) are
deﬁned as clusters of cells no greater than 0.2mm and desig-
nated pN0(i+). The clinical signiﬁcance of micrometastases
and isolated tumor cells continues to be investigated. Recent
studies have evaluated the prognostic impact of isolated
tumor cells or micrometastases in breast cancer and have
found that there was a statistically signiﬁcant decrease in 5-
yeardisease-freesurvivalrateinwomenwithfavorableearly-
stage breast cancer who did not undergo adjuvant treatment
comparedtotheadjuvanttherapygroupalthoughtheimpact
that this should exert on clinical decision making remains
unclear [13, 14].
An understanding of tumor cell distribution and its
relationship to lymphatic ﬂow is important to highlight the
signiﬁcance of our ﬁndings. Unﬁltered lymph ﬂuid ﬂows
regionally through aﬀerent lymph channels, traverses the
outer capsule through the cortex, and ﬂows through the
paracortex to the medulla. The ﬁltered ﬂuid then exits in the
lymph node through the eﬀerent channel via the hilum. One
study utilizing three-dimensional reconstruction to evaluate
metastatic tumor cell distribution in sentinel lymph nodes
found metastases to be located at the aﬀerent pole in 17
of 19 tumor-involved sentinel nodes [15]. In seven nodes,
metastases were conﬁned to the aﬀerent pole, with the
balance containing metastases extending to the eﬀerent pole.
However, only two cases displayed metastases conﬁned to
the eﬀerent pole. These ﬁndings correlate with our study
results, showing that the aﬀerent pole contained the majority
of metastases. In addition, the hotspot was located in the
aﬀerent pole on the cortical surface of the node in the
majority of both the positive and negative sentinel nodes for
our study. We could, therefore, postulate that focusing in the
area of the hotspot would improve the sensitivity of nodal
analysis.
A limitation of our study is the small sample size.
The study spanned just over a year, and the number of
involvednodesislow.Thestandarduseofaxillaryultrasound
pairedwithﬁne-needleaspirationbiopsy(USFNA)aspartof
staging new breast cancers at our institution has decreased4 International Journal of Breast Cancer
the number of intraoperatively detected nodal metastases.
Based on our previously published data, our institutional
policy has been to recommend axillary USFNA for all
invasive ductal carcinomas greater that 1.5cm [16]. This
strategy biases the study cohort towards low-volume axillary
disease. Nonetheless, there are patients where USFNA is of
limited success due to body habitus, patient tolerability, or
the receipt of neoadjuvant chemotherapy.
Notably all patients in this study were hormone receptor
positive. This also is likely related to the institutional interest
in neoadjuvant chemotherapy trials. Given the documented
role for systemic therapy in hormone receptor negative
breast cancer, the majority of these patients are treated
neoadjuvantly at our institution.
As the results of ACoSOG Z-0011 modify our current
practices, intraoperative nodal analysis may become less
prevalent, except in those groups where the trial results
are not applicable, such as patients who will not receive
wholebreastradiotherapy,patientswithmorethan3positive
sentinel nodes, and patients undergoing mastectomy. As the
mastectomy rate has been about 30–40% and is increasing
nationally combined with the evolving strategies for less
comprehensive breast radiotherapy, our results remain rel-
evant to many patients [17]. Furthermore, understanding
the patterns of disease spread may aid in reducing the false
negative results in nodal evaluation and allow for more
eﬀective utilization of ever tightening resources.
5. Conclusion
In patients where the results of intraoperative assessment
of the sentinel node will impact proceeding to axillary
dissection, focusing the examination to the aﬀerent pole and
within 4mm of the hot spot should enhance intraoperative
detection of sentinel node metastasis.
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